167 related articles for article (PubMed ID: 16649351)
1. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
[TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
3. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Le Page E; Leray E; Edan G;
Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
[TBL] [Abstract][Full Text] [Related]
5. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
[TBL] [Abstract][Full Text] [Related]
7. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2007 Jan; 10(1):59-64. PubMed ID: 17198456
[TBL] [Abstract][Full Text] [Related]
9. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
10. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
11. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
[TBL] [Abstract][Full Text] [Related]
12. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis.
De Castro S; Cartoni D; Millefiorini E; Funaro S; Gasperini C; Morino S; Tallarico D; Beni S
J Clin Pharmacol; 1995 Jun; 35(6):627-32. PubMed ID: 7665724
[TBL] [Abstract][Full Text] [Related]
14. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Benesova Y; Stourac P; Beranek M; Kadanka Z
Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
[TBL] [Abstract][Full Text] [Related]
16. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
17. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Bernitsas E; Wei W; Mikol DD
Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Gonsette RE
J Neurol Sci; 2003 Feb; 206(2):203-8. PubMed ID: 12559512
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Esposito F; Radaelli M; Martinelli V; Sormani MP; Martinelli Boneschi F; Moiola L; Rocca MA; Rodegher M; Comi G
Mult Scler; 2010 Dec; 16(12):1490-9. PubMed ID: 20810516
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
